Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs.

Despite efforts to control influenza virus infection and transmission of influenza virus still causes significant morbidity and mortality in the global human population each year. Most of the vaccines currently targeting the immunodominant viral surface glycoprotein hemagglutinin. Cat Recombinant Proteins However, reducing the severity of disease and viral shedding has also been associated with antibody targeting the viral surface glycoprotein, the neuraminidase. 

Importantly, immune antineuraminidase proved to be relatively wide, in contrast to the vaccine-induced antibodies to hemagglutinin head domain. In this study, we assessed the recombinant neuraminidase protein vaccination due to its ability to prevent or limit virus transmission. We vaccinated guinea pigs either intramuscular or intranasal influenza B virus neuraminidase to assess whether vaccination recombinant neuraminidase through these routes can prevent transmission of the virus homologous to the naive recipient. guinea pigs vaccinated with neuraminidase showed reduced viral titers; However, vaccination via the intranasal route is entirely preventable transmission of the virus to naive animals. 

We found high levels antineuraminidase neuraminidase antibodies that inhibit the enzymatic activity in the nasal wash intranasally vaccinated animals, which may explain the observed differences in transmission. We also ensure that the mucosal immune to neuraminidase uninterrupted transmission efficiency heterologous influenza virus B, although to a lesser extent. Finally, we found that the neuraminidase-vaccinated animals are still susceptible to infection through the air and contact transmission route. 

However, the virus titer was significantly lower is detected at the receiver vaccinated. In summary, our data indicate that supplementation with neuraminidase vaccine formulations and vaccination via the intranasal route can widely prevent transmission of influenza B viruses.IMPORTANCE More recently, the effect of anti-neuraminidase immune protection has been highlighted by several studies in humans and animal models. However, so far the role of the Fungal Recombinant Proteins anti-neuraminidase immune inhibition plays virus transmission has not been explored. Additionally, neuraminidase has been overlooked as an influenza virus vaccine antigen. We show here that a vaccine based on neuraminidase can inhibit influenza virus transmission. 

Therefore, neuraminidase should be regarded as an antigen to increase influenza virus vaccine which protects individuals not only from disease but also inhibits further spread of the virus in the population.